

PATENT
ATTORNEY DOCKET NO.: 056291-5179

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION of:

NEWCOMBE et al.

Application No.: 10/507,169

Filed: September 9, 2004

FOR: 4-IMIDAZOLYL SUBSTITUTED
PYRIMIDINE DERIVATIVES WITH CDK
INHIBITORY ACTIVITY

)
)
)
)
) Group Art Unit:
)
) Examiner:
)
)
)

Commissioner for Patents
U.S. Patent and Trademark Office
Customer Service Window, Mail Stop _____
Randolph Building
401 Dulany Street
Alexandria, VA 22314

Date: February 15, 2005

Sir:

INFORMATION DISCLOSURE STATEMENT

Citation of Related U.S. Patent Applications

The Examiner's attention is directed to the following related co-pending U.S. patent applications:

Examiner's Initials	Inventor	U.S. Serial No. U.S. Filing Date	U.S. Patent No. Issued:	PCT Publication No. PCT Publication Date
	Breault et al.	09/763,705 02/26/2001		WO 00/12485 Mar 9, 2000
	Breault et al.	10/771,118 02/04/2004		WO 00/12485 Mar 9, 2000
	Breault et al.	09/763,681 02/26/2001	6,632,820 10/14/2003	WO 00/12486 March 9, 2000
	Bradbury et al.	09/868,602 06/20/2001	6,593,326 07/15/2003	WO 00/39101 July 6, 2000
	Breault et al.	09/914,788 09/05/2001	6,716,831 04/06/2004	WO 00/53595 Sept. 14, 2000

Examiner's Initials	Inventor	U.S. Serial No. U.S. Filing Date	U.S. Patent No. Issued:	PCT Publication No. PCT Publication Date
	Breault	09/958,077 10/04/2001	6,670,368 12/30/2003	WO 00/59892 Oct. 12, 2000
	Pease et al.	10/203,154 08/06/2002	6,649,608 11/18/2003	WO 01/64655 Sept. 7, 2001
	Pease et al.	10/220,139 08/28/2002		WO 01/64654 Sept. 7, 2001
	Pease et al.	10/203,025 08/05/2005	6,838,464 01/04/2005	WO 01/64656 Sept. 7, 2001
	Pease et al.	10/995,931 11/24/2004		WO 01/64656 Sept. 7, 2001
	Pease et al.	10/203,549 08/08/02	6,710,052 03/23/2004	WO 01/64653 Sept. 7, 2001
	Pease et al.	10/753,959 01/09/2004		WO 01/64653 Sept. 7, 2001
	Thomas et al.	10/069,019 02/21/2002	6,855,719 02/15/05	WO 01/14375 A1 March 1, 2001
	Thomas	10/239,790 09/25/2002		WO 01/72717 Oct. 4, 2001
	Thomas et al.	10/332,275 01/07/2003	Allowed 10/08/2004	WO 01/04429 Jan. 17, 2002
	Breault et al.	10/363,655 03/04/2003		WO 02/20512 Mar. 14, 2002
	Thomas	10/467,886 08/13/2003	6,844,341 01/18/05	WO 02/066481 A1 Aug. 29, 2002
	Newcombe	10/479,041 11/26/2003		WO 02/096887 A1 Dec. 5, 2002
	Newcombe et al.	10/507,162 09/09/2004		WO 03/076435 A1 Sept. 18, 2003
	Newcombe et al.	10/507,081 09/09/2004		WO 03/076436 A1 Sept. 18, 2003
	Newcombe et al.	10/507,163 09/09/2004		WO 03/076433 A1 Sept. 18, 2003

A copy of the specification and claims for each application, in the form of the published PCT application from which such application was filed, has previously been provided or is being filed herewith. Copies of the U.S. patent documents are not enclosed.

PLEASE DO NOT PRINT the above information on the patent resulting from the subject application.

Consideration of each listed application is earnestly solicited since unpublished patent applications are contemplated as IDS material; see the exception in Rule 98(a)(2)(iii) and note the penultimate sentence of MPEP 609.

Further, in keeping with MPEP 609, Subsec. C(2), 2nd para., line 10 to end of the paragraph (especially note lines 18-25) PLEASE RETURN A COPY OF THIS LETTER with the Examiner's initials adjacent each above listing so that applicant will know that each listed application has been considered as required by PTO policy.

Citation of Documents

Attached is a Form PTO-1449 listing the enclosed foreign patent documents. Copies of the U.S. patent documents are not enclosed.

The present Information Disclosure Statement is being filed before the mailing date of the first Office Action on the merits, and therefore no certification under 37 CFR §1.97(e) or fee under 37 CFR §1.17(p) is required.

Should a first Action on the merits have been issued on the same day as or before this IDS is filed, please accept this IDS under Rule 97(c) and charge the requisite fee to our Deposit Account under Order No. 056291-5179 and proceed to consider this IDS.


This Information Disclosure Statement is intended to be in full compliance with the rules, but should the Examiner find any part of its required content to have been omitted, prompt notice to that effect is earnestly solicited, along with additional time under Rule 97(f), to enable Applicant to fully comply.

Consideration of the foregoing and enclosures plus the return of a copy of the herewith filed Form PTO-1449 with the Examiner's initials in the left column per MPEP 609 along with an early action on the merits of this application are earnestly solicited.

Except for issue fees payable under 37 C.F.R. §1.18, the Director is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§1.16 and 1.17 which may be required, including any required

extension of time fees, or credit any overpayment to Deposit Account No. 50-0310. This paragraph is intended to be a **CONSTRUCTIVE PETITION FOR EXTENSION OF TIME** in accordance with 37 C.F.R. §1.136(a)(3).

Respectfully Submitted,
Morgan Lewis & Bockius LLP



Date: February 15, 2005
Morgan Lewis & Bockius LLP
Customer No. **09629**
1111 Pennsylvania Avenue, N.W.
Washington, D.C. 20004
Tel. No.: 202-739-3000
DJB:mk

By:

Donald J. Bird
Registration No. 25,323
Tel. No.: (202) 739-5320
Fax No.: (202) 739-3001

FORM PTO-1449 (modified) To: U.S. Department of Commerce Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date: February 15, 2005					Attorney Docket No.		Client Ref.	
					056291-5179			
					Applicant: NEWCOMBE et al.			
					Appln. No.: 10/507,169			
					Filing Date: September 9, 2004			
					Examiner: Unassigned		Group Art Unit: Unassigned	

FOREIGN PATENT DOCUMENTS						English Abstract		Translation Readily Available	
		Document Number	Date MM/YYYY	Country	Inventor/Applicant Name	Enclosed	No	Enclosed	No
	AR	01/29009 A1	04/2001	WO	Davis et al.				
	BR	01/30778 A1	05/2001	WO	Révész et al.				
	CR	01/47897 A1	07/2001	WO	Moriarty et al.				
	DR	01/47921 A1	07/2001	WO	Erickson et al.				
	ER	01/60816 A1	08/2001	WO	Armstead et al.				
**	FR	01/64653 A1	09/2001	WO	Pease et al.				
**	GR	01/64655 A1	09/2001	WO	Pease et al.				
**	HR	01/64656 A1	09/2001	WO	Pease et al.				
**	IR	01/72717 A1	10/2001	WO	Thomas et al.				
**	JR	02/066481 A1	08/2002	WO	Thomas				
**	KR	02/096887 A1	12/2002	WO	Newcombe et al.				
**	LR	03/076433 A1	09/2003	WO	Newcombe et al.				
**	MR	03/076435 A1	09/2003	WO	Newcombe et al.				
**	NR	03/076436 A1	09/2003	WO	Newcombe et al.				
	OR	03/007955 A2	01/2003	WO	Hickson et al.				

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)									
	PR	Boschelli et al., "Synthesis and Tyrosine Kinase Inhibitory Activity of a Series of 2-Amino-8- <i>H</i> -pyrido[2,3- <i>d</i>]pyrimidines: Identification of Potent, Selective Platelet-Derived Growth Factor Receptor Tyrosine Kinase Inhibitors, J. Med. Chem., Vol. 41, 1998, pp. 4365-4377							
	QR	Deady et al., "Reactions of some Quinazoline Compounds with Ethoxymethylenemalononic Acid Derivatives", J. Heterocyclic Chem., Vol. 26, 1989, pp. 161-168							
	RR	El-Kerdawy et al.; "2,4-Bis (Substituted)-5-Nitropyrimidines of Expected Diuretic Action"; Egypt J. Chem. Vol. 29, No. 2, 1986, pp. 247-251							
	SR	Fiziol Akt Veshchestva, 1975, Vol. 7, pp. 68-72					X		X
	TR	Ghosh et al.; "2,4-Bis(arylamino)-5-methylpyrimidines as Antimicrobial Agents"; J. Med. Chem., 1967, Vol. 10, No. 5, pp. 974-975;							
	UR	Ghosh, "2,4-Bis(Arylamino)-6-Methyl Pyrimidines as Antimicrobial Agents", J. Indian Chem. Soc., Vol. 58, No. 5, 1981, pp. 512-513							
	VR	Schmidt et al.; "A Convenient Synthesis of 2-substituted 4-Amino-5-pyrimidinecarbonitriles"; J. Heterocycle Chem., 1997, Vol. 24, No. 5, pp. 1305-1307							
	WR	Zimmermann et al., "Phenylamino-Pyrimidine (PAP) Derivatives: A New Class of Potent and Selective Inhibitors of Protein Kinase C (PKC), Arch. Pharm. Pharm. Med. Chem., Vol. 329, 1996, pp. 371-376							

Examiner	Date Considered:
----------	------------------

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.